<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00643617</url>
  </required_header>
  <id_info>
    <org_study_id>ACCP002.2</org_study_id>
    <nct_id>NCT00643617</nct_id>
  </id_info>
  <brief_title>CyberKnife Radiosurgery For Low &amp; Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry</brief_title>
  <official_title>Prospective Evaluation of CyberKnife Stereotactic Radiosurgery for Low and Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Accuray Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Accuray Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of CyberKnife radiosurgery in&#xD;
      patients with early stage organ-confined prostate cancer and to evaluate the effects of this&#xD;
      treatment on the quality of life over time.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, CyberKnife radiosurgery will be used to produce dose distributions comparable&#xD;
      to those created by HDR brachytherapy treatment, without the use of invasive catheters. The&#xD;
      radiosurgery volumes will closely be made to resemble HDR brachytherapy therapeutic volumes&#xD;
      with similar dose limitation objectives to adjacent normal tissues.&#xD;
&#xD;
      The CyberKnife Robotic Radiosurgery System is a unique radiosurgical system capable of&#xD;
      treating tumors anywhere in the body noninvasively and with sub-millimeter accuracy. The&#xD;
      CyberKnife System delivers radiation using a precise targeting methodology allowing a focal&#xD;
      treatment margin around the target, thus limiting the volume of adjacent tissue receiving&#xD;
      high doses radiation. This in turn allows the delivery of high doses of radiation to the&#xD;
      prostate over a short series of treatments.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2007</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine biochemical disease free survival (using both ASTRO and Phoenix definitions) and measure the rates of acute and late genitourinary and gastrointestinal toxicities following CyberKnife radiosurgery.</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To compare the CyberKnife biochemical disease free survival rates (bDFS) to published HDR monotherapy bDFS rates reported in the literature.</measure>
    <time_frame>10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To measure the rates of local failure, distant failure, clinical-disease free survival, disease-specific survival, overall survival and quality of life.</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">253</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostatic Cancer</condition>
  <condition>Prostatic Neoplasms</condition>
  <condition>Prostate Neoplasms</condition>
  <condition>Cancer of the Prostate</condition>
  <arm_group>
    <arm_group_label>Heterogeneous dose</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>38 Gy delivered in 4 fractions of 9.5 Gy per fraction with CyberKnife Stereotactic Radiosurgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>CyberKnife Stereotactic Radiosurgery</intervention_name>
    <description>38 Gy delivered in 4 fractions of 9.5 Gy per fraction</description>
    <arm_group_label>Heterogeneous dose</arm_group_label>
    <other_name>CyberKnife</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must be at least 18 years of age&#xD;
&#xD;
          -  Histologically proven prostate adenocarcinoma&#xD;
&#xD;
          -  Biopsy within 1 year of date of registration&#xD;
&#xD;
          -  Clinical Stage T1b-T2b, N0, M0&#xD;
&#xD;
          -  Patients belonging to one of the following risk categories:&#xD;
&#xD;
          -  Low Risk: CS T1b-T2a, Gleason Score 2-6, PSA &lt; or = 10 ng/ml&#xD;
&#xD;
          -  Intermediate Risk: CS T2b, Gleason Score 2-6, PSA &lt; or = 10 ng/ml or CS T1b-T2b,&#xD;
             Gleason Score 2-6, PSA &lt; or = 20 ng/ml or CS T1b-T2b, Gleason Score 7 and PSA &lt; or =&#xD;
             10 ng/ml&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical Stage T2c or greater&#xD;
&#xD;
          -  Prior prostatectomy or cryotherapy of the prostate&#xD;
&#xD;
          -  Prior radiotherapy fo the prostate or lower pelvis&#xD;
&#xD;
          -  Implanted hardware or other material that would prohibit appropriate treatment&#xD;
             planning or delivery&#xD;
&#xD;
          -  History of an invasive malignancy other than basal or squamous skin cancers in the&#xD;
             last 5 years&#xD;
&#xD;
          -  Hormone ablation for two months prior to enrollment or during treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald B Fuller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CyberKnife Centers at San Diego, CA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Mardirossian, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>CyberKnife Centers of San Diego, CA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mitchell Cancer Center University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Regional Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial Medical Center</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pasadena Cyberknife Center</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CyberKnife Centers of San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose Cancer Center</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Cyberknife</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Millenium CyberKnife</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JFK Comprehensive Cancer Center</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Florida Radiation Oncology</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elmhurst Memorial Hospital</name>
      <address>
        <city>Elmhurst</city>
        <state>Illinois</state>
        <zip>60126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benefis Health System - Sletten Cancer Institute</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AtlantiCare Regional Medical Center</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anthony Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Texas Medical Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.accuray.com</url>
    <description>Accuray Website</description>
  </link>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 20, 2008</study_first_submitted>
  <study_first_submitted_qc>March 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2008</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>CyberKnife</keyword>
  <keyword>Stereotactic Radiosurgery</keyword>
  <keyword>Radiosurgery</keyword>
  <keyword>Prostate Tumor</keyword>
  <keyword>Prostate Surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

